AhR Effector Scaffold for Bladder Tissue Regeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Patients with severe and end-stage urinary bladder dysfunction due to radiation treatment, interstitial cystitis, spina bifida, or trauma have limited treatment options for bladder tissue replacement, leading to complications such as urinary incontinence, infections, and renal dysfunction.
Innovation Solution
Administration of a pharmaceutical composition containing an aryl hydrocarbon receptor (AhR) effector, such as stemregenin 1 (SR1), to regenerate bladder tissue, promote vascularization, and enhance peripheral nerve innervation, thereby increasing bladder capacity and reducing symptoms of bladder dysfunction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Volume of moving object
If intestinal segments are used for bladder augmentation, then bladder capacity and compliance are increased, but complications such as infection, electrolyte imbalances, mucus and stone formation, spontaneous perforation, and malignancy risk increase
Solution Approach 1:
The patent extracts and eliminates the use of intestinal segments from bladder augmentation procedures. Instead, it employs a biodegradable scaffold implanted directly into the bladder that delivers growth factors to stimulate regeneration of native bladder tissue, thereby avoiding the complications associated with using intestinal segments while still achieving increased bladder capacity
Solution Approach 2:
The patent introduces a biodegradable scaffold as an intermediary carrier that releases growth factors (such as FGF-2, VEGF, and PDGF) to stimulate bladder tissue regeneration. This scaffold acts as a mediator between the implantation site and the regeneration process, enabling tissue regeneration without requiring intestinal segments
2Reliability
If surgical intervention is performed for bladder tissue replacement, then bladder dysfunction is addressed, but the procedure complexity and recovery time increase
Solution Approach 1:
The patent applies preliminary action by implanting a biodegradable scaffold containing growth factors before the bladder tissue fully regenerates. The scaffold is placed in advance to deliver growth factors that stimulate and guide the regeneration process, simplifying the overall surgical intervention and reducing recovery time compared to traditional bladder replacement procedures
3Volume of moving object
If traditional bladder augmentation is performed, then bladder capacity is increased, but the quality of regenerated tissue (muscle to collagen ratio) is compromised
Solution Approach 1:
The patent changes the biological parameters of tissue regeneration by using a biodegradable scaffold that releases specific growth factors (FGF-2, VEGF, PDGF). These growth factors alter the regeneration process to produce a balanced muscle to collagen ratio, improving tissue quality while maintaining increased bladder capacity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method results in the regeneration of bladder tissue with a 1:1 muscle to collagen ratio, increased vascularization, and peripheral nerve innervation, leading to recovery of up to 100% of pre-surgery bladder capacity and reduced symptoms of bladder dysfunction.
Implementation Method 1
administering to the subject a pharmaceutical composition comprising an effective amount of an aryl hydrocarbon receptor (AhR) effector for regenerating bladder tissue in the subject
Implementation Method 2
the scaffold comprises poly (1,8 octanediol-co-citrate) (POC)
Data Source
AI summary
Disclosed are methods for regenerating bladder tissue. More specifically, disclosed are methods of regenerating bladder tissue by administering aryl hydrocarbon receptor effectors to a subject in need thereof.